{"hands_on_practices": [{"introduction": "Translating complex genetic data into a clinically actionable prediction is a core challenge in pharmacogenomics. This exercise introduces the concept of an activity score, a widely used model to quantify the functional impact of different UGT1A1 alleles. By assigning numerical weights to alleles and summing them, we can create a simple yet powerful system to categorize patients into predicted metabolizer phenotypes, providing a foundational step for personalized drug therapy. [@problem_id:4573033]", "problem": "A central objective in clinical pharmacology is to rationally translate genotype into predicted enzyme activity to inform dosing. For the glucuronidation pathway catalyzed by UDP-glucuronosyltransferase family 1 member A1 (UGT1A1), consider the following mechanistic premises grounded in biochemistry and pharmacogenomics:\n\n1. Under conditions where substrate concentrations are comparable across individuals and the Michaelis–Menten constant is unaffected by genotype, the initial reaction velocity $v$ is proportional to the maximal velocity $V_{\\max}$, and $V_{\\max}$ is proportional to the active enzyme concentration $[E]$. Thus, predicted catalytic capacity is proportional to $[E]$.\n\n2. In a diploid genome, the total active enzyme concentration $[E]$ is the sum of contributions from the two alleles, assuming no dominant-negative interactions or compensatory regulation, i.e., $[E] \\propto a_{1} + a_{2}$, where $a_{i}$ is the per-allele activity contribution.\n\n3. The reference allele UGT1A1\\*1 is a normal function allele, while UGT1A1\\*28 is a decreased function allele due to promoter thymine–adenine repeat expansion that lowers transcription efficiency. For the purpose of constructing a quantitative activity score, assign per-allele activity weights $w_{N} = 1.0$ for normal function and $w_{D} = 0.5$ for decreased function.\n\n4. Normalize the diplotype activity score $S$ to be the sum of the two per-allele weights, so that the maximum possible score is $S_{\\max} = 2.0$. Define phenotype bins by relative capacity cutpoints anchored to clinically meaningful fractions of $S_{\\max}$: poor metabolizer if $S \\leq 1.0$, intermediate metabolizer if $1.0 < S < 1.5$, and normal metabolizer if $S \\geq 1.5$.\n\nTasks:\n- Using only the premises above and first-principles reasoning about additivity of allele contributions to enzyme concentration, construct the activity score model and compute the activity scores $S$ for the UGT1A1\\*1/UGT1A1\\*1, UGT1A1\\*1/UGT1A1\\*28, and UGT1A1\\*28/UGT1A1\\*28 diplotypes.\n- Determine the phenotype category for each diplotype according to the cutpoints provided. For reporting compactness, internally encode phenotype as a numeric code: poor metabolizer $= 0$, intermediate metabolizer $= 1$, normal metabolizer $= 2$.\n- For the final boxed answer, report only a single row matrix containing, in order, the three activity scores $S$ for UGT1A1\\*1/UGT1A1\\*1, UGT1A1\\*1/UGT1A1\\*28, and UGT1A1\\*28/UGT1A1\\*28. Do not include phenotype codes in the final boxed answer.\n\nNo rounding is required; report exact values. No units are to be provided, as the scores are unitless.", "solution": "The problem statement is evaluated as scientifically grounded, well-posed, and objective. It provides a clear, self-contained model for translating genetic information (diplotypes) into a quantitative activity score and a categorical phenotype. All premises are consistent and sufficient for arriving at a unique solution. The model, while a simplification of complex biological reality, is a standard and valid heuristic used in the field of pharmacogenomics. Therefore, a solution is warranted.\n\nThe core of the problem is to construct and apply a quantitative activity score model based on the provided premises.\n\nPremise 1 establishes a direct proportionality between initial reaction velocity $v$ and the total active enzyme concentration $[E]$, such that catalytic capacity $\\propto [E]$.\nPremise 2 posits an additive model for the total enzyme concentration based on contributions from each of the two alleles in a diploid genome: $[E] \\propto a_{1} + a_{2}$, where $a_i$ is the activity contribution from allele $i$.\nCombining these, the catalytic capacity is proportional to the sum of the per-allele contributions.\n\nPremise 3 assigns quantitative weights to the per-allele contributions. Let $w_{\\text{allele}}$ be the activity weight for a given allele.\nFor the normal function allele UGT1A1\\*1, the weight is $w_{N} = 1.0$.\nFor the decreased function allele UGT1A1\\*28, the weight is $w_{D} = 0.5$.\n\nPremise 4 defines the diplotype activity score, $S$, as the sum of the weights of the two alleles present in the diplotype. For a diplotype composed of allele $A$ and allele $B$, the score is given by the model:\n$$S = w_{A} + w_{B}$$\n\nUsing this model, we will compute the activity scores for the three specified diplotypes.\n\n1.  **UGT1A1\\*1/UGT1A1\\*1 (homozygous normal/wild-type):**\n    This individual has two copies of the UGT1A1\\*1 allele. The activity score, which we denote as $S_{1/1}$, is the sum of the weights for each of these two alleles.\n    $$S_{1/1} = w_{\\text{UGT1A1*1}} + w_{\\text{UGT1A1*1}} = w_{N} + w_{N} = 1.0 + 1.0 = 2.0$$\n\n2.  **UGT1A1\\*1/UGT1A1\\*28 (heterozygous):**\n    This individual has one copy of the UGT1A1\\*1 allele and one copy of the UGT1A1\\*28 allele. The activity score, $S_{1/28}$, is the sum of their respective weights.\n    $$S_{1/28} = w_{\\text{UGT1A1*1}} + w_{\\text{UGT1A1*28}} = w_{N} + w_{D} = 1.0 + 0.5 = 1.5$$\n\n3.  **UGT1A1\\*28/UGT1A1\\*28 (homozygous decreased function):**\n    This individual has two copies of the UGT1A1\\*28 allele. The activity score, $S_{28/28}$, is the sum of the weights for each of these two alleles.\n    $$S_{28/28} = w_{\\text{UGT1A1*28}} + w_{\\text{UGT1A1*28}} = w_{D} + w_{D} = 0.5 + 0.5 = 1.0$$\n\nNext, we determine the phenotype for each diplotype using the provided cutpoints and numeric codes (poor metabolizer $= 0$, intermediate metabolizer $= 1$, normal metabolizer $= 2$).\nThe phenotype bins are defined as:\n- Poor metabolizer: $S \\leq 1.0$\n- Intermediate metabolizer: $1.0 < S < 1.5$\n- Normal metabolizer: $S \\geq 1.5$\n\n-   For the UGT1A1\\*1/UGT1A1\\*1 diplotype, the score is $S_{1/1} = 2.0$. Since $2.0 \\geq 1.5$, the phenotype is **normal metabolizer** (code $2$).\n\n-   For the UGT1A1\\*1/UGT1A1\\*28 diplotype, the score is $S_{1/28} = 1.5$. Since $1.5 \\geq 1.5$, the phenotype is **normal metabolizer** (code $2$). The score falls on the boundary, and the definition for normal metabolizer is inclusive of $1.5$.\n\n-   For the UGT1A1\\*28/UGT1A1\\*28 diplotype, the score is $S_{28/28} = 1.0$. Since $1.0 \\leq 1.0$, the phenotype is **poor metabolizer** (code $0$). The score falls on the boundary, and the definition for a poor metabolizer is inclusive of $1.0$.\n\nThe problem demands that the final answer be a row matrix containing only the three activity scores in the specified order: UGT1A1\\*1/UGT1A1\\*1, UGT1A1\\*1/UGT1A1\\*28, and UGT1A1\\*28/UGT1A1\\*28.\nThe calculated scores are $2.0$, $1.5$, and $1.0$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n2.0 & 1.5 & 1.0\n\\end{pmatrix}\n}\n$$", "id": "4573033"}, {"introduction": "Building on the concept of altered enzyme activity, we now explore the direct biochemical consequences using the principles of enzyme kinetics. This practice applies the Michaelis-Menten equation to model how a genetically determined reduction in UGT1A1 enzyme concentration impacts the metabolic rate of a crucial substrate. This demonstrates the quantitative link between a lower $V_{\\max}$ and the reduced clearance capacity that predisposes patients to drug toxicity. [@problem_id:4573068]", "problem": "A hepatic microsomal preparation is used to study glucuronidation of SN-38, the active metabolite of irinotecan, by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1). Consider two genotypes: a reference genotype with full UGT1A1 expression and a reduced-expression genotype in which enzyme expression is halved due to a promoter polymorphism, while substrate binding affinity is unchanged. Assume the elementary enzyme mechanism under initial rate conditions and the quasi-steady-state approximation:\n$$\nE + S \\xrightleftharpoons[k_{-1}]{k_{1}} ES \\xrightarrow{k_{\\mathrm{cat}}} E + P,\n$$\nwith total enzyme concentration $[E]_{T}$, and define $K_{m}$ and $V_{\\max}$ using standard enzyme kinetics.\n\nFor both genotypes, the substrate concentration is $[S]=2\\ \\mu\\mathrm{M}$ and the Michaelis constant is $K_{m}=5\\ \\mu\\mathrm{M}$. The reference genotype has $V_{\\max}=100\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$, while the reduced-expression genotype has $V_{\\max}=50\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$.\n\nStarting from the mechanism and definitions above, derive the expression for the initial reaction velocity $v$ as a function of $V_{\\max}$, $K_{m}$, and $[S]$. Then compute $v$ for each genotype at $[S]=2\\ \\mu\\mathrm{M}$. Round your computed velocities to four significant figures. Express $v$ in $\\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$.\n\nFinally, based solely on your computed velocities and assuming comparable hepatic uptake and distribution between genotypes, briefly interpret the pharmacological consequence for systemic SN-38 exposure in the reduced-expression genotype relative to the reference genotype.", "solution": "The problem is subjected to validation and is deemed valid. It is scientifically grounded in the principles of enzyme kinetics and pharmacogenomics, it is well-posed with sufficient and consistent data, and it is expressed in objective, formal language. We may therefore proceed with the solution.\n\nThe problem requires the derivation of the initial reaction velocity expression, computation of the velocity for two genotypes, and a pharmacological interpretation of the results.\n\n**1. Derivation of the Initial Reaction Velocity Expression**\n\nThe enzymatic reaction is described by the following mechanism:\n$$ E + S \\xrightleftharpoons[k_{-1}]{k_{1}} ES \\xrightarrow{k_{\\mathrm{cat}}} E + P $$\nwhere $E$ is the enzyme (UGT1A1), $S$ is the substrate (SN-38), $ES$ is the enzyme-substrate complex, and $P$ is the product (SN-38 glucuronide). The rate constants for the association, dissociation, and catalytic steps are $k_1$, $k_{-1}$, and $k_{\\mathrm{cat}}$, respectively.\n\nThe rate of change of the enzyme-substrate complex concentration, $[ES]$, is given by:\n$$ \\frac{d[ES]}{dt} = k_{1}[E][S] - k_{-1}[ES] - k_{\\mathrm{cat}}[ES] = k_{1}[E][S] - (k_{-1} + k_{\\mathrm{cat}})[ES] $$\nThe problem states to assume the quasi-steady-state approximation (QSSA), which posits that the concentration of the intermediate complex $[ES]$ remains nearly constant after a very brief initial phase of the reaction. Therefore, we set its rate of change to zero:\n$$ \\frac{d[ES]}{dt} \\approx 0 $$\nThis implies that the rate of formation of $ES$ is equal to its rate of breakdown:\n$$ k_{1}[E][S] = (k_{-1} + k_{\\mathrm{cat}})[ES] $$\nThe total enzyme concentration, $[E]_T$, is the sum of the free enzyme, $[E]$, and the enzyme bound in the complex, $[ES]$:\n$$ [E]_T = [E] + [ES] $$\nFrom this conservation equation, we can express the free enzyme concentration as $[E] = [E]_T - [ES]$. Substituting this into the steady-state equation gives:\n$$ k_{1}([E]_T - [ES])[S] = (k_{-1} + k_{\\mathrm{cat}})[ES] $$\nOur goal is to solve for $[ES]$. Expanding the left side yields:\n$$ k_{1}[E]_T[S] - k_{1}[ES][S] = (k_{-1} + k_{\\mathrm{cat}})[ES] $$\nRearranging the terms to isolate $[ES]$:\n$$ k_{1}[E]_T[S] = (k_{-1} + k_{\\mathrm{cat}})[ES] + k_{1}[ES][S] $$\n$$ k_{1}[E]_T[S] = (k_{-1} + k_{\\mathrm{cat}} + k_{1}[S])[ES] $$\nSolving for $[ES]$:\n$$ [ES] = \\frac{k_{1}[E]_T[S]}{k_{-1} + k_{\\mathrm{cat}} + k_{1}[S]} $$\nTo simplify this expression, we divide the numerator and the denominator by $k_1$:\n$$ [ES] = \\frac{[E]_T[S]}{\\frac{k_{-1} + k_{\\mathrm{cat}}}{k_1} + [S]} $$\nStandard enzyme kinetics defines the Michaelis constant, $K_m$, as:\n$$ K_m = \\frac{k_{-1} + k_{\\mathrm{cat}}}{k_1} $$\nSubstituting $K_m$ into the expression for $[ES]$ yields:\n$$ [ES] = \\frac{[E]_T[S]}{K_m + [S]} $$\nThe initial reaction velocity, $v$, is the rate of product formation, which is proportional to the concentration of the $ES$ complex:\n$$ v = \\frac{d[P]}{dt} = k_{\\mathrm{cat}}[ES] $$\nSubstituting the derived expression for $[ES]$ into the velocity equation gives:\n$$ v = k_{\\mathrm{cat}} \\frac{[E]_T[S]}{K_m + [S]} = \\frac{k_{\\mathrm{cat}}[E]_T[S]}{K_m + [S]} $$\nThe maximum velocity, $V_{\\max}$, is achieved when the enzyme is fully saturated with substrate, i.e., when $[ES] = [E]_T$. In this case, $v = V_{\\max} = k_{\\mathrm{cat}}[E]_T$. Substituting this definition into the velocity equation gives the final Michaelis-Menten equation:\n$$ v = \\frac{V_{\\max}[S]}{K_m + [S]} $$\nThis is the required expression for the initial reaction velocity $v$.\n\n**2. Computation of Reaction Velocity for Each Genotype**\n\nWe will now use the derived equation to compute the initial velocity for the reference and reduced-expression genotypes at a substrate concentration of $[S] = 2\\ \\mu\\mathrm{M}$.\n\nFor both genotypes, the Michaelis constant is given as $K_m = 5\\ \\mu\\mathrm{M}$.\n\n**Reference Genotype:**\nThe maximum velocity for the reference genotype is $V_{\\max, \\text{ref}} = 100\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$.\nThe initial velocity, $v_{\\text{ref}}$, is:\n$$ v_{\\text{ref}} = \\frac{V_{\\max, \\text{ref}}[S]}{K_m + [S]} = \\frac{(100\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1})(2\\ \\mu\\mathrm{M})}{5\\ \\mu\\mathrm{M} + 2\\ \\mu\\mathrm{M}} $$\n$$ v_{\\text{ref}} = \\frac{200}{7}\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} \\approx 28.5714\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} $$\nRounding to four significant figures, the velocity for the reference genotype is:\n$$ v_{\\text{ref}} = 28.57\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} $$\n\n**Reduced-Expression Genotype:**\nThe maximum velocity for the reduced-expression genotype is $V_{\\max, \\text{red}} = 50\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$. This is consistent with the problem statement that enzyme expression is halved, as $V_{\\max}$ is directly proportional to the total enzyme concentration $[E]_T$.\nThe initial velocity, $v_{\\text{red}}$, is:\n$$ v_{\\text{red}} = \\frac{V_{\\max, \\text{red}}[S]}{K_m + [S]} = \\frac{(50\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1})(2\\ \\mu\\mathrm{M})}{5\\ \\mu\\mathrm{M} + 2\\ \\mu\\mathrm{M}} $$\n$$ v_{\\text{red}} = \\frac{100}{7}\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} \\approx 14.2857\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} $$\nRounding to four significant figures, the velocity for the reduced-expression genotype is:\n$$ v_{\\text{red}} = 14.29\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} $$\nAs expected, the calculated reaction velocity for the reduced-expression genotype is half that of the reference genotype ($14.29/28.57 \\approx 0.5$).\n\n**3. Interpretation of Pharmacological Consequence**\n\nThe calculated velocity, $v$, represents the rate of metabolic clearance of SN-38 via glucuronidation in this in vitro system. The reduced-expression genotype exhibits a metabolic rate ($v_{\\text{red}} = 14.29\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$) that is half that of the reference genotype ($v_{\\text{ref}} = 28.57\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$).\n\nAssuming this in vitro finding translates to in vivo pharmacology and that other factors like hepatic uptake and distribution are comparable, a reduced rate of SN-38 metabolism will lead to slower clearance of the active metabolite from the body. Consequently, patients with the reduced-expression UGT1A1 genotype will experience higher and more prolonged systemic exposure (i.e., a larger area under the concentration-time curve, AUC) to SN-38. Since SN-38 is the primary agent of both the therapeutic effect and the major dose-limiting toxicities (e.g., severe neutropenia and diarrhea) of irinotecan, this increased exposure significantly heightens the risk of severe adverse drug reactions.", "answer": "$$\n\\boxed{\\begin{pmatrix} 28.57 & 14.29 \\end{pmatrix}}\n$$", "id": "4573068"}, {"introduction": "While a genotype may be known to reduce enzyme function, its true clinical utility depends on its ability to predict adverse events in a patient population. This final practice integrates principles of population genetics and clinical epidemiology to calculate the Positive Predictive Value (PPV) of the UGT1A1*28/*28 genotype for irinotecan-induced neutropenia. Mastering this calculation is essential for critically evaluating the evidence supporting the use of pharmacogenomic tests in clinical practice. [@problem_id:4573073]", "problem": "A pharmacogenomics team is assessing the predictive utility of the uridine diphosphate-glucuronosyltransferase isoform 1A1 (UDP-glucuronosyltransferase 1A1, UGT1A1) promoter polymorphism known as UGT1A1*28 for irinotecan-induced neutropenia in an ethnically homogeneous cohort. Assume the following scientifically grounded context and parameters:\n\n- The cohort receives a standard irinotecan regimen producing a cohort-wide incidence of grade $3$–$4$ neutropenia of $I = 0.18$ during the first two cycles.\n- The UGT1A1 locus obeys Hardy–Weinberg equilibrium at the allele level, with the UGT1A1*28 allele frequency $q = 0.30$. Let the wild-type allele frequency be $p = 1 - q$.\n- Genotype-specific risks are multiplicatively related to a baseline risk as follows: individuals with UGT1A1*1/*1 have relative risk $RR_{*1/*1} = 1$, those with UGT1A1*1/*28 have $RR_{*1/*28} = 1.5$, and those with UGT1A1*28/*28 have $RR_{*28/*28} = 2.5$.\n- Genotyping is assumed analytically valid (no misclassification), and neutropenia is treated as a binary clinical event within the assessment window.\n\nDefine the positive predictive value (PPV) as the probability of grade $3$–$4$ neutropenia conditional on a “positive test,” where a positive test is the homozygous UGT1A1*28 genotype (UGT1A1*28/*28). Using only the definitions of conditional probability, Hardy–Weinberg equilibrium for genotype frequencies, and the law of total probability, compute the PPV of UGT1A1*28/*28 for grade $3$–$4$ neutropenia in this cohort. Round your final answer to four significant figures and express it as a decimal fraction without a percentage sign.", "solution": "The problem statement has been critically validated and is deemed scientifically grounded, well-posed, and objective. All necessary parameters are provided, and there are no internal contradictions or violations of fundamental principles. The problem is solvable as stated.\n\nThe objective is to compute the positive predictive value (PPV) of the UGT1A1*28/*28 genotype for irinotecan-induced neutropenia. The problem explicitly defines PPV as the conditional probability of developing grade $3$–$4$ neutropenia, denoted by the event $N$, given that an individual has the homozygous UGT1A1*28 genotype, denoted by $G_{*28/*28}$. Thus, we must calculate $\\text{PPV} = P(N | G_{*28/*28})$.\n\nFirst, we determine the frequencies of the three possible genotypes (UGT1A1*1/*1, UGT1A1*1/*28, and UGT1A1*28/*28) using the principle of Hardy–Weinberg equilibrium. Let $q$ be the frequency of the UGT1A1*28 allele and $p$ be the frequency of the UGT1A1*1 (wild-type) allele.\n\nThe problem provides the frequency of the UGT1A1*28 allele:\n$$q = 0.30$$\nThe frequency of the wild-type allele is therefore:\n$$p = 1 - q = 1 - 0.30 = 0.70$$\n\nAccording to Hardy–Weinberg equilibrium, the genotype frequencies are given by $p^2$, $2pq$, and $q^2$:\nFrequency of the wild-type homozygous genotype, $P(G_{*1/*1})$:\n$$P(G_{*1/*1}) = p^2 = (0.70)^2 = 0.49$$\nFrequency of the heterozygous genotype, $P(G_{*1/*28})$:\n$$P(G_{*1/*28}) = 2pq = 2(0.70)(0.30) = 0.42$$\nFrequency of the variant homozygous genotype, $P(G_{*28/*28})$:\n$$P(G_{*28/*28}) = q^2 = (0.30)^2 = 0.09$$\nAs a check, the sum of genotype frequencies is $0.49 + 0.42 + 0.09 = 1.00$.\n\nNext, we establish the relationship between the genotype-specific risks and the overall incidence of neutropenia, $I$. The problem states that the risks are multiplicative relative to a baseline risk. Let $R_0$ be the probability of neutropenia in the baseline group, which is the UGT1A1*1/*1 genotype with a relative risk of $RR_{*1/*1}=1$.\n$$R_0 = P(N | G_{*1/*1})$$\nThe risks for the other genotypes are:\n$$P(N | G_{*1/*28}) = R_0 \\times RR_{*1/*28} = R_0 \\times 1.5$$\n$$P(N | G_{*28/*28}) = R_0 \\times RR_{*28/*28} = R_0 \\times 2.5$$\n\nThe cohort-wide incidence of neutropenia, $I = P(N) = 0.18$, can be expressed using the law of total probability, summing the risks for each genotype weighted by their respective frequencies:\n$$P(N) = P(N|G_{*1/*1})P(G_{*1/*1}) + P(N|G_{*1/*28})P(G_{*1/*28}) + P(N|G_{*28/*28})P(G_{*28/*28})$$\nSubstituting the known values and expressions for risk:\n$$I = (R_0 \\times 1)(p^2) + (R_0 \\times 1.5)(2pq) + (R_0 \\times 2.5)(q^2)$$\nWe can factor out the unknown baseline risk, $R_0$:\n$$I = R_0 [1 \\cdot p^2 + 1.5 \\cdot (2pq) + 2.5 \\cdot q^2]$$\nNow, we substitute the given incidence $I=0.18$ and the calculated genotype frequencies:\n$$0.18 = R_0 [(1)(0.49) + (1.5)(0.42) + (2.5)(0.09)]$$\n$$0.18 = R_0 [0.49 + 0.63 + 0.225]$$\n$$0.18 = R_0 (1.345)$$\nWe can now solve for the baseline risk, $R_0$:\n$$R_0 = \\frac{0.18}{1.345}$$\n\nThe quantity we need to compute is the PPV, which is defined as the risk of neutropenia in individuals with the UGT1A1*28/*28 genotype:\n$$\\text{PPV} = P(N | G_{*28/*28})$$\nUsing the relationship defined earlier:\n$$\\text{PPV} = R_0 \\times RR_{*28/*28} = R_0 \\times 2.5$$\nSubstitute the expression for $R_0$:\n$$\\text{PPV} = \\left(\\frac{0.18}{1.345}\\right) \\times 2.5$$\n$$\\text{PPV} = \\frac{0.18 \\times 2.5}{1.345} = \\frac{0.45}{1.345}$$\nPerforming the division:\n$$\\text{PPV} \\approx 0.3345724907...$$\nThe problem requires the answer to be rounded to four significant figures.\n$$\\text{PPV} \\approx 0.3346$$\nThis value represents the probability that a person with the UGT1A1*28/*28 genotype will experience grade $3$–$4$ neutropenia under the specified conditions.", "answer": "$$\\boxed{0.3346}$$", "id": "4573073"}]}